NCT03123952No Longer Available不适用
Expanded Access to ABT-414
AbbVie0 个研究点开始时间: 2017年4月21日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 发起方
研究概览
简要总结
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to ABT-414 prior to approval by the local regulatory agency. Availability will depend on territory eligibility. Participating sites will be added as they apply for and are approved for the EAP. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participant must have epidermal growth factor receptor (EGFR) amplification or EGFRvIII mutation.
- •Health Care Provider (HCP) must have prior clinical trial experience with ABT-
- •The participant must not be eligible for an ABT-414 clinical trial.
- •Pediatric participants may be evaluated on a case by case basis.
排除标准
- 未提供
研究者
相似试验
Available
不适用
Expanded Access to Telisotuzumab AdizutecanNCT05982873AbbVie
No Longer Available
不适用
Expanded Access to ABBV-8E12Primary Tauopathy Corticobasal Degeneration Syndrome (CBD)NCT03744546AbbVie
No Longer Available
不适用
Expanded Access to ABBV-787Acute Myeloid LeukemiaNCT06439966AbbVie
Available
不适用
Expanded Access to ABBV-CLS-484Advanced Solid Tumor CancerNCT06188975Calico Life Sciences LLC
No Longer Available
不适用
Expanded Access to Bimatoprost (Durysta)Open-angle GlaucomaNCT05338606AbbVie